Navigation Links
NuVasive to Host Investor Reception on September 11, 2007
Date:9/7/2007

Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.

The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.

NuVasive senior management at the reception will include:

* Alex Lukianov, Chairman and Chief Executive Officer

* Keith Valentine, President and Chief Operating Officer

* Kevin O'Boyle, Executive Vice President and Chief Financial Officer

* Pat Miles, Executive Vice President of Marketing and Development

* Jeff Rydin, Senior Vice President, U.S. Sales

* Jason Hannon, Senior Vice President and General Counsel

Participants in the physician panel will include:

* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant

Clinical Professor at SUNY, Buffalo, NY

* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine

Institute, Austin, TX

* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and

Beth Israel Hospitals and Assistant Professor of Neurological Surgery

at Albert Einstein College of Medicine, New York, NY

* Faheem Sandhu, MD, Assistant Professor, Department of Neurosurgery and

Director of Complex and Minimally Invasive Spinal Surgery at Georgetown

University Hospital, Washington, DC.

A live Web cast of the investor reception presentations will be available online from the investor relations page of the Company's corporate Web site at http://www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, http://www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $3.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(TM), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed (particularly with respect to the ongoing clinical trial for NeoDisc(TM)); the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's financial projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at http://www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. NuVasive further cautions you that the opinions expressed by the physician- participants in the investor reception are entirely their own, have not been developed or scripted by NuVasive, should not be attributed to NuVasive, and may prove to be inaccurate.

Contact: Investors:

Kevin C. O'Boyle Nick Laudico/Zack Kubow

EVP & Chief Financial Officer The Ruth Group

NuVasive, Inc. 646-536-7030/7020

858-909-1800 nlaudico@theruthgroup.com

investorrelations@nuvasive.com zkubow@theruthgroup.com

Media:

Jason Rando

The Ruth Group

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Investor warns of angel-venture funding gap
3. Brazilian bio-industry should impress American investors
4. Investors raise $25 million for biodiesel plant
5. Bio-energy and cleantech grab attention of investors
6. Venture Investors to open Michigan office
7. Early-stage executives hear from investors
8. Commerce qualifies seven for investor tax credits
9. Investor links East Coast funds to Midwest tech
10. Angel investors commit $12.7B in first half of `06
11. Wisconsin investors the lifeblood of New Jersey biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... ... towards leveraging the years of diagnostic excellence by Mayo Clinic and the experience ... product suite will be distributed through the Microsoft Azure platform and will focus ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... Heinz as Executive Director of Strategic Planning. His extensive background in consulting, ... Chuck’s professional experience encompasses marketing and differentiation consulting, business strategy development, new ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ (VIC™), is ... directors. This addition continues to strengthen and diversify VIC’s board. , "We are ... “He is a highly accomplished business executive with a broad range of experience directly ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):